142
Participants
Start Date
February 19, 2021
Primary Completion Date
March 31, 2025
Study Completion Date
December 31, 2025
L19TNF
Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
Lomustine
Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
NOT_YET_RECRUITING
Hôpital Neurologique Pierre Wertheimer, Bron
NOT_YET_RECRUITING
Hôpital Saint Louis, Paris
NOT_YET_RECRUITING
Sorbonne University, AP-HP, Paris brain institute, Paris
RECRUITING
University Hospital Bonn, Bonn
NOT_YET_RECRUITING
University Hospital Köln, Cologne
RECRUITING
Klinikum rechts der Isar, München
RECRUITING
Universitatsklinikum Tubingen, Tübingen
RECRUITING
Azienda USL di Bologna IRCCS delle Scienze Neurologiche di Bologna, Bologna
RECRUITING
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan
RECRUITING
Istituto Oncologico Veneto IRCCS, Padua
NOT_YET_RECRUITING
Azienda Ospedaliero-Universitaria Senese Policlinico Le Scotte, Siena
NOT_YET_RECRUITING
AOU Città della Salute e della Scienza di Torino, Torino
RECRUITING
Inselspital Universitätsklinik für Medizinische Onkologie Bern, Bern
RECRUITING
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne
RECRUITING
Universitatspital Zurich - Klinik fur Neurologie & Hirntumorzentrum, Zurich
Philogen S.p.A.
INDUSTRY